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Dual-functionalisation of gelatine nanoparticles
with an anticancer platinum(II)–bisphosphonate
complex and mineral-binding alendronate†
Kambiz Farbod,a Alessandra Curci,b Mani Diba,a Tatiana Zinkevich,c
Arno P. M. Kentgens,c Michele Iaﬁsco,d Nicola Margiottab
and Sander C. G. Leeuwenburgh*a
In order to improve the eﬃcacy of therapeutic systems to treat bone tumours, novel drug delivery vehicles
should be developed that have strong and speciﬁc aﬃnity to mineralised tissue and at the same time are
able to release anticancer molecules locally in a controlled and sustained manner. Recently, we
developed mineral-binding gelatine nanoparticles with enhanced aﬃnity to calcium phosphate by
conjugating alendronate (ALN) molecules onto their surface. Herein, we have enhanced the functionality
of these nanoparticles by rendering them potentially therapeutically active via covalent linking of an
anticancer platinum–bisphosphonate (Pt–BP) complex. Diﬀerent functionalisation schemes and molar
ratios between reactants were screened and the eﬀective functionalisation of gelatine nanoparticles with
Pt–BP (or with both Pt–BP and ALN) was assessed. Our results revealed that the degree of
functionalisation could be tailored by varying the molar ratio of Pt–BP and ALN relative to glutaraldehyde
used as crosslinker. A sustained and tunable release of platinum as a function of the initial Pt–BP/ALN/
glutaraldehyde molar ratio was achieved for both Pt–BP- and dual-functionalised gelatine nanoparticles.
Moreover, dual-functionalised gelatine nanoparticles also displayed a high aﬃnity to hydroxyapatite-
coated surfaces thanks to the presence of ALN. Summarising, it was demonstrated that mineral-binding
gelatine nanoparticles can be loaded with tailored amounts of anticancer molecules, which may beneﬁt
the development of bone-seeking carriers for targeted delivery of drugs to treat bone tumours.
Introduction
Bone is a frequent site for metastases, which develop in up to
70% of patients with prostate cancer and breast cancer,1 and in
up to 30% of those with cancers of the lung, bladder and
thyroid.2 Bone metastases are a health and economic burden as
they are associated with numerous skeletal-related issues
including pathological fractures, spinal cord compression,
pain, need for radiation therapy or surgery to bone.3 Besides the
devastating eﬀect of cancer on bone tissue, current treatment
modalities not specic to cancer cells result in damaging
normal cells and healthy tissues.4 In fact, a major disadvantage
of anticancer drugs is their lack of selectivity for tumour tissue,
which causes severe side eﬀects and results in low cure rates.5
For instance, therapy with platinum-based chemotherapeutic
molecules (e.g. cisplatin (cis-diamminedichloridoplatinum(II))),
which are a group of key drugs used in the treatment of several
types of cancers, are associated with various secondary eﬀects
including anemia, nausea, vomiting, neurotoxicity and neph-
rotoxicity. These side eﬀects impair the patient's quality of life
and can even be life-threatening.6–8
To overcome these side eﬀects, the design of a new generation
of molecules to target traditional anticancer platinum-based drugs
to bone tissue is strongly required.8 To this end, platinum–
bisphosphonate complexes (i.e. bis-{ethylenediamineplatinum(II)}-
2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate (Pt–BP) and bis-
{ethylenediamineplatinum(II)}-medronate) were recently devel-
oped.9–11 Bisphosphonate-functionalised platinum-based mole-
cules not only target bone as a result of the bone-seeking
properties of bisphosphonate moieties,12–14 but also specically
select bone tumours15 due to their higher metabolic activity as
compared to healthy cells.16
Traditional systemic delivery of chemotherapeutics,
however, entails high systemic drug elimination through renal
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and urinary excretion and limited circulation time.17 On the
contrary, chemotherapeutic drugs would be delivered more
eﬃciently to bone tumours upon bone-specic and sustained
delivery from suitable carriers,18,19 thereby reducing toxic side
eﬀects in unaﬀected tissues. To this end, novel and more
eﬀective drug delivery vehicles should be developed that have
strong and specic aﬃnity to mineralised tissue and are able
to release anticancer drugs locally in a controlled and sustained
manner.5,20
The intrinsic biocompatibility, biodegradability and ease
of functionalisation of natural polymers are of great potential
value for applications in tissue engineering, regenerative
medicine, pharmaceutics and drug delivery.21,22 Gelatine is
a particularly attractive candidate material for drug delivery,
since it is a low-cost proteinaceous biopolymer that has been
extensively used for biomedical purposes thanks to its
biocompatible, biodegradable and non-toxic properties.18,22–25
Gelatine can be tuned with respect to its drug loading eﬃ-
ciency,26 degradation rate and release kinetics,25,27 which
renders gelatine a remarkably versatile drug carrier for a wide
variety of biomedical applications.27,28 For applications as a drug
delivery vehicle, gelatine has been processed into diﬀerent
shapes and forms, such as hydrogels,29,30 sponges,31–34 coatings
or lms,35–37 microparticles38–42 and nanoparticles.6,43–47 Gelatine
microparticles have been used as carriers of anticancer drugs
such as cisplatin.48,49 Although cisplatin was only adsorbed onto
gelatine microparticles, the anticancer eﬀect was enhanced and
prolonged as compared to carrier-free delivery of cisplatin
alone.48 Microparticles, however, lack the mobility and size
required for targeted delivery and are oen entrapped in non-
target organs.38 Sub-micron or nanoparticles, on the contrary,
have gained increased research interest,50 due to their signi-
cantly smaller size and thus increased specic surface area,
which enhances the drug payload and facilitates targeted
delivery to specic tissues.51
Gelatine nanoparticles have been used for the delivery of both
hydrophilic and hydrophobic anticancer drugs.18,52 Drug-loaded
gelatine nanoparticles have also demonstrated rapid uptake and
long-term retention in the tumour aer administration.18,19 The
superior eﬃcacy of anticancer drug-loaded gelatine nano-
particles compared to free drug has been validated both in vitro
(in cancer cell lines) and in vivo (in tumour-bearing animal
models).18,19,52–55 Cytotoxicity analysis of anticancer drug-loaded
gelatine nanoparticles against diﬀerent cancer cell lines has
shown higher anticancer activity as compared to the free drug.
This has been attributed to greater endocytotic uptake of gela-
tine nanoparticles in cancer cells.52,56,57 Gelatine nanoparticles,
however, have not yet been developed for bone-specic drug
delivery. Recently, we developed mineral-binding gelatine
nanoparticles with enhanced aﬃnity to calcium phosphate
(CaP).12 Herein, we attempt to link—for the rst time—novel
bone-specic gelatine nanoparticles to a chemotherapeutic Pt–
BP drug in order to render them potentially chemotherapeuti-
cally active. Pt–BP loading was done using two diﬀerent methods
(i.e. via covalent attachment or physical adsorption), while the
eﬀect of the drug loading was analysed in detail with respect to
the physicochemical properties of the carriers including their
mineral-binding capacity as well as the release kinetics of the
drug. The functionalisation reactions were carried out using
diﬀerent reaction schemes and molar ratios between the reac-
tants and were characterised using 13C and 31P Solid-State
Nuclear Magnetic Resonance (SS-NMR) spectroscopy, Energy-
Dispersive X-ray (EDX) spectroscopy and Inductively Coupled
Plasma-Optical Emission Spectrometry (ICP-OES). The eﬃcacy
of conjugation as well as the retention and release properties of
the Pt–BP-loaded gelatine nanoparticles were investigated using
ICP-OES. Finally, the inuence of dual functionalisation with Pt–
BP and ALN on the aﬃnity of gelatine nanoparticles to CaP was
assessed using uorescent microscopy.
Experimental section
Materials
Gelatine type B (from bovine skin, 225 Bloom, average molec-
ular mass: 50 kDa, pI  5, 33 millimoles of free amino
groups58 and 100–115 millimoles of carboxyl groups per 100 g
gelatine) was purchased from Sigma-Aldrich. Glutaraldehyde
(GA, 25 wt% solution in water) was purchased from Acros
Organics. Alendronic acid (ALN, (4-amino-1-hydroxy-
butylidene)diphosphonic acid) was purchased from AK Scien-
tic, Inc. (AKSci, Union City, CA, USA). Acetone was purchased
from Boom BV (Meppel, the Netherlands). 2-Ammonium-1-
hydroxyethane-1,1-diyl-bisphosphonic acid (AHBP-H5) and
[Pt(OSO3)(OH2)(en)] (en ¼ ethylenediamine) were prepared
following procedures reported previously.9 Milli-Q water was
used to dissolve the platinum compounds. All other reagents
were purchased from Sigma-Aldrich.
Preparation and characterisation of Pt–BP complex
[{Pt(en)}2(m-AHBP-H2)](HSO4) (bis-{ethylenediamineplatinum(II)}-
2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate), Pt–BP (Fig. 1),
was prepared according to already reported methods.16,59 Briey,
2-ammonium-1-hydroxyethane-1,1-diyl-bisphosphonic acid
(AHBP-H5) (0.055 g, 0.246 mmol) was dissolved in Milli-Q water
(18 ml) and the resulting solution, maintained at 40 C, was rst
partially neutralised with Ba(OH)2$8H2O (0.082 g, 0.258 mmol)
and subsequently treated with a solution of [Pt(OSO3)(OH2)(en)]
(0.200 g, 0.541 mmol, in 14 ml of Milli-Q water). The obtained
suspension was kept under magnetic stirring at 40 C overnight
and then cooled down in an ice bath. The white precipitate
(BaSO4) was removed by ltration through a plug of Celite® and
Fig. 1 Chemical structure of platinum–bisphosphonate (Pt–BP).
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the ltrate was concentrated to a volume of approximately 2 ml.
The pH of the concentrated solution was adjusted to 1.0 by
addition of H2SO4 (1 M) and the acidic solution was treated with
methanol, which induced precipitation of the desired product.
The precipitate was le standing at 4 C for 3 h and then isolated
by ltration, washed with methanol and diethyl ether and dried
under vacuum. Obtained 0.183 g (85% yield). Anal. calc. for
[{Pt(en)}2(m-AHBP-H2)](HSO4)$3H2O (C6H29N5O14P2Pt2S, Mw ¼
879.4 g mol1): C, 8.19%; H, 3.32%; N, 7.96%. Found: C, 8.49%;
H, 3.19%; N, 7.64%. ESI-MS: calc. for [{Pt(en)}2(m-AHBP-H2)]
+
([C6H22N5O7P2Pt2]
+) ¼ 728.03; found: m/z (% relative to the base
peak) ¼ 727.8 (100) [M]+.
The spectroscopic characterisation of Pt–BP was consistent
with literature data (1H and 13P NMR spectroscopy and
Fourier Transform Infrared Spectroscopy (FTIR)). Electrospray
Ionisation-Mass Spectrometry (ESI-MS) was carried out using an
electrospray interface and ion trap mass spectrometer (1100
Series LC/MSD Trap system Agilent, Palo Alto, CA). Elemental
analyses were carried out using a Hewlett Packard 185 C, H andN
analyser.
The dinuclear Pt–BP complex was found to be stable in
neutral aqueous solution even aer standing for several months
at room temperature, as evidenced by NMR spectroscopy (data
not shown).
Preparation of unfunctionalised gelatine nanoparticles
Gelatine nanoparticles (Gel) were prepared using a two-step
desolvation method as previously reported.12,60,61 Subse-
quently, GA was used to crosslink the nanoparticles with
a molar ratio of GA relative to the amine groups in gelatine (GA/
NH2) of 2. Aer crosslinking at room temperature for 16 h
(although 3–4 h crosslinking was suﬃcient to obtain stable
nanoparticles, the reaction was aged for 16 h to obtain the
highest yield), 100 ml of glycine solution (100 mM) was added to
the gelatine nanoparticles suspension to block the unreacted
aldehyde groups. Aer three cycles of centrifugation (5000 rpm
for 60 min, Universal 32 R Hettich Centrifuge, Tuttlingen,
Germany) and resuspension in Milli-Q water by vortexing, the
pH of the suspensions was adjusted to 7.0. To investigate the
properties of the gelatine nanoparticles in swollen state, small
fractions of the suspension were stored at 4 C until further use,
whereas the rest of the nanoparticles were lyophilised (no
cryoprotectant applied; Freezone 4.5, Labconco, USA) and
stored at 4 C.
Preparation of alendronate-functionalised gelatine
nanoparticles
ALN-functionalised gelatine nanoparticles (Gel$ALN) were
prepared according to an already reported method.12 Briey,
using a two-step desolvation method, gelatine nanoparticles
were prepared as previously described.12,60,61 Subsequently, GA
was used to crosslink gelatine nanoparticles with a GA/NH2
molar ratio of 2. Residual aldehyde groups from the GA cross-
linking reaction were used for further conjugation with the
amine (NH2) groups of ALN. ALN was added to the gelatine
nanoparticles suspension aer aging the crosslinking reaction
for 16 h (post-functionalisation, no pH manipulation (pH  4)).
The conjugation reaction was carried out at room temperature
with molar ratios of ALN relative to GA (ALN/GA) of 0.12, 2.5 and
5. Aer three cycles of centrifugation (5000 rpm for 60 min) and
resuspension in Milli-Q water by vortexing, the pH of the
suspension was adjusted to 7.0. To investigate the properties of
the functionalised gelatine nanoparticles in swollen state, small
fractions of the suspension were stored at 4 C until further use,
whereas the rest of the nanoparticles were lyophilised and
stored at 4 C.
Preparation of Pt–BP-functionalised gelatine nanoparticles
Gelatine nanoparticles were prepared using a two-step des-
olvation method as previously reported.12,60,61 Subsequently, GA
was used to crosslink gelatine nanoparticles with a GA/NH2
molar ratio of 2. Residual aldehyde groups from the GA cross-
linking reaction were used for further conjugation with the
amine (NH2) groups of Pt–BP. Pt–BP was added to the gelatine
nanoparticles suspension aer aging the crosslinking reaction
for 16 h (post-functionalisation, no pH manipulation (pH  4)).
The conjugation reaction was carried out at room temperature.
The eﬃciency of the conjugation reaction was investigated at Pt–
BP/GA molar ratios of 0.06, 0.12, 0.24 and 0.48. Aer three cycles
of centrifugation (5000 rpm for 60 min) and resuspension in
Milli-Q water by vortexing, the pH of the suspensions was
adjusted to 7.0. To investigate the properties of the functional-
ised gelatine nanoparticles in swollen state, small fractions of the
suspension were stored at 4 C until further use, whereas the rest
of the gelatine nanoparticles were lyophilised and stored at 4 C.
Preparation of dual-functionalised gelatine nanoparticles
Gelatine nanoparticles were prepared using a two-step des-
olvation method as reported previously.12,60,61 Subsequently,
GA was used to crosslink gelatine nanoparticles with a GA/NH2
molar ratio of 2. Residual aldehyde groups from the GA cross-
linking reaction were used for further conjugation with the
amine (NH2) groups of both ALN and Pt–BP. To evaluate
and optimise the dual conjugation reaction, diﬀerent func-
tionalisation schemes and molar ratios between the reactants
were selected for the addition of ALN and Pt–BP to the
suspension of gelatine nanoparticles (see Table 1 for an over-
view of the abbreviations, compositions and functionalisation
parameters):
 Gelatine nanoparticles functionalised with ALN only
(Gel$ALN);
 Gelatine nanoparticles functionalised with Pt–BP only
(Gel$Pt);
 Gelatine nanoparticles simultaneously functionalised with
ALN and Pt–BP (Gel$ALN$Pt-Sim);
 Gelatine nanoparticles sequentially functionalised with
ALN and Pt–BP (Gel$ALN//Pt);
 Gelatine nanoparticles sequentially functionalised with Pt–
BP and ALN (Gel$Pt//ALN).
All the conjugation reactions were carried out at room
temperature aer aging the GA crosslinking reaction for 16 h.
Aer three cycles of centrifugation (5000 rpm for 60 min) and
This journal is © The Royal Society of Chemistry 2016 RSC Adv., 2016, 6, 113025–113037 | 113027
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resuspension in Milli-Q by vortexing, the pH of the suspension
was adjusted to 7.0 by using 1 or 0.1 M NaOH solutions. To
investigate the properties of the functionalised gelatine nano-
particles in swollen state, small fractions of the suspension were
stored at 4 C until further use, whereas the rest of the nano-
particles were lyophilised and stored at 4 C.
As a control experiment, similar amounts of Pt–BP and ALN
(Table 1) were physically adsorbed onto a suspension of
unfunctionalised gelatine nanoparticles (GA/NH2 molar ratio ¼
2; crosslinked at room temperature for 16 h; blocked with
100ml of 100mM glycine solution). Aer addition of Pt–BP and/
or ALN to the suspension of unfunctionalised gelatine nano-
particles, the mixture was le stirring at room temperature for
16 h, aer which the gelatine nanoparticles were centrifuged
(5000 rpm for 60 min) and resuspended in Milli-Q water by
vortexing three times. The pH of the nal suspension was
adjusted to 7.0 by using 1 or 0.1 M NaOH solutions. To inves-
tigate the properties of the nanoparticles in swollen state, small
fractions of the suspension were stored at 4 C until further use,
whereas the rest of the nanoparticles were lyophilised and
stored at 4 C.
Characterisation of gelatine nanoparticles
Electron microscopy. The morphology and size of the gela-
tine nanoparticles were characterised in lyophilised state using
Scanning Electron Microscopy (SEM, JEOL 6340F; all samples
were mounted on aluminium stubs using carbon tape and
sputter-coated with gold–palladium). Digital image analysis
soware (Image J, NIH) was applied to analyse the diameter of
at least 200 nanoparticles using scanning electron micrographs
in lyophilised state.
Water content. To study the inuence of Pt–BP functionali-
sation as well as the dual functionalisation on the crosslinking
eﬃciency of the gelatine nanoparticles, their water content was
measured according to a method described previously.12 Briey,
10 mg of gelatine nanoparticles were soaked overnight at
room temperature in 2 ml of Milli-Q water while agitated on
a shaking table at 90 rpm. The swollen nanoparticles were
collected aer 24 h on lter paper to remove surface water and
placed in a vial of known weight (Wvial). The weight of the vial
including the swollen nanoparticles was then recorded
(Wswollen+vial). Aer lyophilising for 24 h, the weight of the vial
including the dry nanoparticles was recorded (Wdry+vial).
Accordingly, the water content (%) of gelatine nanoparticles was
calculated as follows:
Water content ð%Þ ¼ ðWswollenþvial WvialÞ 

Wdryþvial Wvial

Wswollenþvial Wvial
 100
¼ Wswollenþvial Wdryþvial
Wswollenþvial Wvial  100
(1)
This parameter provides an indication of the water uptake
(wt%) of the gelatine nanoparticles. Five samples were
measured for each experimental group.
Dynamic light scattering and laser doppler velocimetry.
Dynamic Light Scattering (DLS) and Laser Doppler Velocimetry
(LDV) were performed on a Zetasizer® Nano-S (Malvern
Instruments Ltd.) to characterise the hydrodynamic size
(dispersed in Milli-Q water, solid content 0.01% w/v) and
z-potential (dispersed in 5 mM HEPES buﬀer at pH 7.0) of the
gelatine nanoparticles, respectively.
z-Potential, size and polydispersity index (PDI) of the nano-
particles were also studied as a function of time at storage
condition (4 C) as well as physiological temperature (37 C).
Elemental analysis. Inductively Coupled Plasma-Optical
Emission Spectrometry (ICP-OES, iCap 6300) was used to
quantify the degree of functionalisation with Pt–BP, dual
functionalisation (Pt–BP and ALN), as well as the retention of
Pt–BP and ALN to the gelatine nanoparticles. To quantify the
degree of functionalisation, the nanoparticles were digested
in concentrated nitric acid (at 37 C overnight on a shaking
Table 1 Abbreviations, compositions and functionalisation parame-
ters of unfunctionalised and (dual-)functionalised gelatine
nanoparticles
Details Abbreviation
Experimental parameters
Functionalisation
scheme
Pt–BP/
GA
molar
ratio
ALN/
GA
molar
ratio
Gelatine
nanoparticles
Gel N/Aa N/Aa N/Aa
Gelatine
nanoparticles
functionalised
with Pt–BP or
ALN
Gel$ALN ALN only — 0.12
2.5
5
Gel$Pt Pt–BP only 0.06 —
0.12
0.24
0.48
Gelatine
nanoparticles
dual-
functionalised
with Pt–BP and
ALN
Gel$ALN$
Pt-Sim
Simultaneous:
ALN and Pt–BP
0.06 0.12
2.5
5
Gel$ALN//Pt Sequential: ALN
rst
0.06 0.12
2.5
5
Gel$Pt//ALN Sequential:
Pt–BP rst
0.06 0.12
2.5
5
0.12 5
0.24
0.48
Gelatine
nanoparticles
with adsorbed
Pt–BP and/or
ALN
Gel$Pt-Ads
(Pt–BP-
adsorbed)
N/Ab 0.06 —
0.12
0.24
0.48
Gel$Pt//ALN-Ads
(Pt–BP and
ALN-adsorbed)
0.06 5
0.12
0.24
0.48
a No ALN- or Pt–BP-functionalisation carried out for Gel. b No ALN- or
Pt–BP-functionalisation, but only physical adsorption, carried out for
Gel$Pt-Ads and Gel$Pt//ALN-Ads.
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table) and subsequently diluted to 1% nitric acid solutions for
ICP-OES analysis of the platinum and phosphorus content.
Solid-state nuclear magnetic resonance (SS-NMR) spectros-
copy. The conjugation reaction was investigated using 13C and
31P solid-state NMR spectroscopy. All 31P solid-state NMR
experiments were performed on a Varian NMR spectrometer
operating at proton frequency of 850 MHz. Spectra were
acquired using a 1.6 mm magic angle spinning (MAS) HXY
probehead at a spinning frequency of 35 kHz. 31P chemical shis
were referenced to the known resonance of H3PO4 (0 ppm).
The temperature was stabilised at 298 K. Single pulse excitation
was used for obtaining the 31P spectra; no proton decoupling
was applied. The recycle delay was 60 s to make sure that
the samples can be interpreted quantitatively. 13C solid-state
Cross-Polarisation Magic Angle Spinning (CPMAS) spectra were
measured by means of a 600 MHz Varian Spectrometer. Samples
were packed into 3.2 mm rotors, employing a MAS rate of
10 kHz. A 90 proton pulse of 2.5 ms excited transverse proton
magnetisation, then 2 ms cross-polarisation pulses were simul-
taneously applied on both – proton and carbon channels – to
induce magnetisation transfer. Two-pulse phase-modulated
(TPPM) decoupling62 at a radiofrequency-eld strength of
100 kHz was used during acquisition. Carbon chemical shis
were referenced with respect to tetramethylsilane (TMS) using
the adamantane signals as a secondary reference.
Alendronic acid (as reference) was crushed to increase the
surface of ALN crystals. As control experiment, Pt–BP and/or Pt–
BP mixed with crushed alendronic acid was mixed with
unblocked and glycine-blocked unfunctionalised gelatine
nanoparticles.
Energy-dispersive X-ray (EDX) spectroscopy. Energy-
dispersive X-ray (EDX) measurements were performed using
a Field Emission Scanning ElectronMicroscope (FE-SEM; Sigma
300, Zeiss, Germany) equipped with an EDX detector (XFlash
detector 610M, Brucker Nano GmbH, Germany). Prior to the
measurements, the samples were coated with a 10 nm thick
chromium layer. Each EDX spectrum was collected for 5 min by
scanning over an area of 1200  900 spots with the spot size of
0.38 mm. The elemental composition of each sample was
determined automatically by the EDX (ESPRIT 2.0) soware.
Retention and release of alendronate and Pt–BP to gelatine
nanoparticles. The retention of Pt–BP and/or ALN to gelatine
nanoparticles was evaluated in Milli-Q water as a function of
soaking time (1, 3, 7 and 14 days). Phosphate buﬀered saline
(PBS), cell culture medium or similar phosphorus-containing
media could not be used for this experiment, since the high
phosphate concentration in the media did not allow for detec-
tion and diﬀerentiation of phosphorus released from dual- or
Pt–BP-functionalised gelatine nanoparticles using ICP-OES.
Briey, 10 mg of lyophilised functionalised gelatine nano-
particles (GA/NH2 molar ratio ¼ 2; pHfunctionalisation ¼ 4) was
added to 10 ml of Milli-Q water at 37 C on a shaking table (70
rpm). At each time point, the suspensions were centrifuged at
5000 rpm for 60 min. The gelatine pellet was separated from the
supernatant and re-suspended in 10 ml of fresh Milli-Q water
for further time points. Aer the last time point, to quantify the
retained Pt–BP and/or ALN, the gelatine pellet was digested in
concentrated nitric acid (at 37 C overnight on a shaking table)
and subsequently diluted to 1% nitric acid solutions for ICP-
OES analysis of the platinum and phosphorus content. To
evaluate the in vitro release of platinum and ALN from gelatine
nanoparticles, the collected supernatants were also mixed with
nitric acid to prepare a 1% nitric acid solution (and kept at 37 C
overnight on a shaking table) for further elemental analysis of
the platinum and phosphorus content using ICP-OES. The
retention and release of Pt–BP and/or ALN to gelatine nano-
particles with adsorbed Pt–BP (and/or ALN) was evaluated
similarly as a control experiment.
Aﬃnity of gelatine nanoparticles to calcium phosphate
Commercially available titanium discs of 12 mm diameter and
1.5 mm thickness were grit-blasted with aluminium oxide
particles, cleaned ultrasonically in isopropanol (15 min) and
air-dried overnight. The surface roughness of the titanium discs
(Ra ¼ 2.0  0.2 mm) was measured using a universal surface
tester (Innowep GmbH, Wu¨rzburg, Germany). Titanium discs
were subsequently coated with a thin hydroxyapatite lm (1.5 
0.1 mm) using a commercially available radiofrequency
magnetron sputter deposition system (Edwards High Vacuum
ESM 100 system, Crawford, England) as described previ-
ously.63,64 The target materials were hydroxyapatite (Ca10(-
PO4)6(OH)2) granules (diameter: 0.5–1.0 mm; CAM Bioceramics
BV, Leiden, the Netherlands). The discs were mounted on
a rotating water-cooled substrate holder. The distance between
target and implant holder was 80 mm. Before sputtering, the
discs were cleaned by etching for 10 min with argon ions.
During deposition (7.5 h), the argon pressure was kept at 5 
103 mbar and the sputter power of 2 times 400 W with
a coating thickness of 1 mm was used. Aer deposition, the
coated implants were subjected to an additional infrared heat
treatment for 30 s at 650 C (Quad Ellipse Chamber, Model E4-
10 P, Research Inc.), as previously described.65 The titanium
discs were eventually cleaned ultrasonically in isopropanol for
15 min to remove any unbound particles, air-dried and stored
at room temperature. The coatings were characterised by thin
lm XRD (PW 1830, PANalytical) and ATR-FTIR (Spectrum
One™, Perkin Elmer).
The aﬃnity of gelatine nanoparticles to CaP was evaluated
by immersing the hydroxyapatite-coated titanium discs for 16 h in
2 ml of gelatine nanoparticle suspension (dispersed at 2.5 mg
ml1 in 5 mM HEPES buﬀer) at 37 C on a shaking plate. The
titanium discs were horizontally placed at the bottom of 24-well
cell culture plates without any constraint for horizontal move-
ment within the well. The autouorescence of gelatine
was exploited to quantify the amount of surface-bound gelatine
nanoparticles by uorescence microscopy using an automated
axio Imager Z1 microscope (Carl Zeiss Micro Imaging GmbH,
Go¨ttingen, Germany) and digital image analysis (Image J, NIH)
aer thoroughly rinsing the discs withMilli-Q water to remove the
unbound gelatine nanoparticles. The aﬃnity of gelatine nano-
particles to the hydroxyapatite surfaces was quantied by dividing
the areas covered by gelatine nanoparticles to the entire
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hydroxyapatite-covered surface area of the titanium discs using
the autouorescence detected from gelatine nanoparticles.
Statistical analysis
All results are depicted as mean  standard deviation. The
statistical analyses were performed using GraphPad Prism
(version 5.03) soware. Diﬀerences among groups were deter-
mined by one-way analysis of variance (ANOVA) with a Bonfer-
roni (multiple comparisons) post-hoc test, and a value of p <
0.05 was considered as signicantly diﬀerent.
Results and discussion
Preparation and characterisation of Pt–BP
The dinuclear Pt(II) complex bis-{ethylenediamineplatinum(II)}-
2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate (Pt–BP,
Fig. 1) was prepared according to a method previously
described.16 Briey, the barium salt of the aminobi-
sphosphonate was rst prepared and subsequently treated with
two equivalents of [Pt(OSO3)(OH2)(en)] (en ¼ ethylenediamine).
The reaction mixture was le under magnetic stirring overnight
at higher temperature (40 C) as compared to the previously
reported procedure.9 The elemental analysis and the spectro-
scopic features were consistent with the data reported in the
literature (data not shown).9,10,66
Preparation and characterisation of gelatine nanoparticles
Eﬀect of functionalisation scheme. Gelatine nanoparticles
(either functionalised or unfunctionalised) were prepared using
an established two-step desolvation method60,61 resulting in the
formation of spherical nanoparticles. Average diameters of the
nanoparticles in lyophilised and swollen state are provided in
Table 2. SEM micrographs revealed that the morphology and
size of Pt–BP-functionalised or dual-functionalised gelatine
nanoparticles in lyophilised state did not change upon func-
tionalisation, as compared to the unfunctionalised ones (Gel)
(Fig. 2). DLS measurements conrmed that the size of func-
tionalised gelatine nanoparticles in swollen state did not
change upon functionalisation (Table 2). Similar results were
obtained for gelatine nanoparticles that were lyophilised and
rehydrated/resuspended in Milli-Q water, 5 mM HEPES buﬀer
or phosphate buﬀered saline (PBS). z-Potential, size and poly-
dispersity index (PDI) measurements at storage condition (4 C)
as well as body temperature (37 C) up to 14 days showed no
signicant diﬀerences as compared to the results shown in
Table 2.
Water content and, hence, the degree of crosslinking of
either Pt–BP- or dual-functionalised gelatine nanoparticles did
not change as compared to unfunctionalised gelatine nano-
particles (Table 2), as ALN and/or Pt–BP were added aer
completion of the crosslinking reaction and functioned mainly
as blocking agents for the unreacted aldehyde groups. These
results were in agreement with our previous ndings for ALN-
functionalised gelatine nanoparticles.12
z-Potential values shown in Table 2 are related to gelatine
nanoparticles (dual-)functionalised at a Pt–BP/GAmolar ratio of
0.06 and/or an ALN/GAmolar ratio of 5. These data revealed that
functionalisation of gelatine nanoparticles with negatively
charged ALN10 rendered the surface of the nanoparticles more
negatively charged, irrespective of the functionalisation scheme
or the Pt–BP/GA molar ratio (data not shown). The Pt–BP
complex is positively charged and becomes neutral aer
conjugation with GA and formation of an imine bond between
the pending NH2 and the aldehydes. However, functionalisation
of gelatine nanoparticles with Pt–BP complex rendered the
surface of the nanoparticles more negatively charged, which
was similar to the z-potential of ALN-functionalised gelatine
nanoparticles. This phenomenon may not be completely
explained by the experiments performed in this study. Never-
theless, we speculate that the change in z-potential may only be
the result of avoiding glycine-blocking the unreacted aldehyde
groups on the surface of gelatine nanoparticles. Another
possible explanation is the hydrolysis of the Pt–O–P bonds in
the conjugated Pt–BP complex, that could occur at neutral pH
with entering of one or more water molecules in the coordina-
tion sphere of platinum and formation of P–O groups. Water
molecules coordinated to positively charged platinum ions are
acidic and tend to deprotonate with formation of neutral Pt–
hydroxido species.67,68 The overall result would be the presence
of P–O groups on the surface of nanoparticles, which could
contribute to lowering the z-potential of the Pt–BP-
functionalised gelatine nanoparticles.
As shown in Fig. 3, ICP-OES measurements conrmed the
presence of platinum in Pt–BP-functionalised gelatine nano-
particles. At the lowest Pt–BP/GA molar ratio of 0.06, it was
possible to link approximately 5.3 moles of Pt–BP to onemole of
gelatine (Gel$Pt[0.06]), whereas for Pt–BP-adsorbed gelatine
nanoparticles with the same Pt–BP/GA molar ratio (Gel$Pt-Ads
[0.06]) only 0.6 moles of Pt–BP per mole of gelatine was
Table 2 Particle size, z-potential and water content of unfunctionalised and (dual-)functionalised gelatine nanoparticlesa
Gel Gel$ALN Gel$Pt Gel$ALN$Pt-Sim Gel$Pt//ALN Gel$ALN//Pt
Particle size (lyophilised, nm)b 179  51 181  48 190  36 187  46 188  32 192  40
Particle size (swollen, nm)b 395  4 401  7 387  11 376  20 394  9 382  15
z-Potential (mV) 18.7  0.6a 29.3  0.7 30.4  2.5 30.2  4.1 27.3  3.0 28.6  1.8
Water content (%) 89.3  2.4 90.2  1.8 89.1  3.1 91.0  2.7 89.9  3.3 91.3  1.6
a The presented results are related to gelatine nanoparticles with Pt–BP/GA molar ratio of 0.06 and/or ALN/GA molar ratio of 5. b Particle sizes of
lyophilised gelatine nanoparticles were measured by analysing at least 200 particles using electron microscopy, whilst the diameters of swollen
nanoparticles were determined by DLS. aDenotes statistical diﬀerences versus the other experimental groups within the same row (p < 0.05).
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detected. By increasing the Pt–BP/GA molar ratio up to 0.48, the
amount of Pt–BP linking increased up to approximately 28
moles of Pt–BP per mole of gelatine. The total amount of Pt–BP
present on gelatine nanoparticles with adsorbed Pt–BP,
however, was signicantly lower as compared to those func-
tionalised with Pt–BP at all Pt–BP/GA molar ratios shown in
Fig. 3.
Fig. 4 shows the weight percentages of platinum and phos-
phorus for all functionalisation schemes in Pt–BP- and dual-
functionalised gelatine nanoparticles (at a xed Pt–BP/GA
molar ratio of 0.06). The ALN content in samples was calcu-
lated by subtracting the amount of phosphorus derived from
Pt–BP from the total amount of detected phosphorus.
Fig. 2 Scanning electron micrographs of gelatine nanoparticles. (a) unfunctionalised (Gel); (b) ALN-functionalised (Gel$ALN); (c) Pt–BP-func-
tionalised (Gel$Pt); (d) simultaneously functionalised with ALN and Pt–BP (Gel$ALN$Pt-Sim); (e) sequentially functionalised with Pt–BP/then/ALN
(Gel$Pt//ALN); (f) sequentially functionalised with ALN/then/Pt–BP (Gel$ALN//Pt) (scale bar ¼ 500 nm).
Fig. 3 Amount of platinum in gelatine nanoparticlesmeasured by ICP-
OES (the left Y-axis represents relative weight percentage of Pt–BP
present in gelatine nanoparticles (wt%), whereas the right Y-axis
represents the molar ratio of Pt–BP relative to gelatine) (p < 0.05);
(Gel$Pt ¼ gelatine nanoparticles with covalently conjugated Pt–BP;
Gel$Pt-Ads ¼ gelatine nanoparticles with physically adsorbed Pt–BP).
Fig. 4 Eﬀect of functionalisation scheme and ALN/GA molar ratio on
the eﬃciency of dual-functionalisation of gelatine nanoparticles
measured by ICP-OES (Y axis represents wt% of Pt–BP and ALN
present in gelatine nanoparticles; Letters “a” and “b” denote statistically
signiﬁcant diﬀerences versus Gel$Pt and Gel$ALN[0.06], respectively)
(p < 0.05).
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Corresponding molar ratios of detected Pt–BP or ALN relative to
gelatine can be found in Fig. S1.† As shown in Fig. 4 and S1,† the
eﬃciency of Pt–BP conjugation reaction decreased regardless of
the applied ALN/GA molar ratio by simultaneous addition of
ALN and Pt–BP to gelatine nanoparticles aer completion of the
GA crosslinking reaction. This was attributed to the competition
between Pt–BP and ALN to react with available free aldehyde
groups on gelatine nanoparticles. Moreover, Pt–BP molecules
were less likely to link to the available free aldehyde groups on
gelatine nanoparticles, since ALN/GA molar ratios were higher
than Pt–BP/GA ratios.
The amount of Pt–BP linked to gelatine nanoparticles
decreased considerably for all ALN/GA molar ratios (Fig. 4)
when the nanoparticles were rst functionalised with ALN. This
is obviously due to the fact that the majority of available free
aldehyde groups on gelatine nanoparticles were already
consumed by the reaction with ALN. The amount of either Pt–
BP or ALN linked to gelatine nanoparticles did not decrease
when the nanoparticles were rst functionalised with Pt–BP
prior to the reaction with ALN. Therefore, the latter dual-
functionalisation scheme and the highest ALN/GA molar ratio
were selected for further experiments.
By increasing the Pt–BP/GA molar ratio up to 0.48, the eﬃ-
ciency of the Pt–BP conjugation reaction for dual-functionalised
gelatine nanoparticles increased (Fig. 5; molar ratios of detected
Pt–BP or ALN in diﬀerent samples can be found in Fig. S2†),
which was similar to our results for Pt–BP-functionalised gela-
tine nanoparticles shown in Fig. 3. However, no signicant
change was observed with respect to the eﬃciency of the ALN
conjugation reaction (Fig. 5 and S2†), which indicated that the
ALN-functionalisation reaction was independent from the
preceding reaction with Pt–BP.
Energy-dispersive X-ray (EDX) spectroscopy conrmed the
presence of platinum on dual- and Pt–BP-functionalised gela-
tine nanoparticles, whereas no platinum was detected on
unfunctionalised and ALN-functionalised gelatine nano-
particles (Fig. S3†). The presence of phosphorus was also
conrmed for gelatine nanoparticles functionalised with
alendronate and Pt–BP (Fig. S3†).
Since the amount of Pt–BP attached to gelatine nanoparticles
relative to the gelatine matrix itself was very low, the obtained
solid-state NMR spectra showed very low signal intensity from
the Pt–BP complex linked to gelatine nanoparticles (Fig. S4†).
Furthermore, 13C spectra are dominated by the gelatine signals,
which overlap all signals from other moieties. As a result, we
could not observe free alendronate signals in the 13C spectrum.
Further investigations using higher Pt–BP concentrations are
required to obtain clear and conclusive solid-state NMR spectra
from (dual-)functionalised gelatine nanoparticles.
Retention of Pt–BP and alendronate to gelatine nano-
particles. To evaluate the extent and stability of the covalent
linking between Pt–BP and gelatine, the retention of Pt–BP to
gelatine nanoparticles was studied as a function of soaking time
in Milli-Q water. Retention tests showed that at the lowest Pt–
BP/GA molar ratio of 0.06, up to 97 wt% of the Pt–BP initially
present on Pt–BP-functionalised gelatine nanoparticles (Gel$Pt
[0.06]) was retained aer 14 days of soaking (Fig. 6a). On the
contrary, less retention of Pt–BP was observed for gelatine
nanoparticles containing adsorbed Pt–BP (Gel$Pt-Ads[0.06]) as
compared to the functionalised ones, since 85 wt% of the
initially bound Pt–BP was retained to Gel$Pt-Ads[0.06] aer only
14 days of soaking. Similarly, higher cumulative release of
platinum (% M/Mtot) was observed for Pt–BP-functionalised
gelatine nanoparticles when compared to the Pt–BP-adsorbed
ones at the lowest Pt–BP/GA ratio of 0.06 (Fig. 6b; Gel$Pt[0.06]
versus Gel$Pt-Ads[0.06]; Fig. 6c and d show statistical analysis of
Fig. 6a and b, respectively, for day 14 only). Up to Pt–BP/GA ratio
of 0.24, Pt–BP-functionalised and Pt–BP-adsorbed gelatine
nanoparticles showed a similar behaviour. Pt–BP-adsorbed
gelatine nanoparticles at highest Pt–BP/GA molar ratio
(Gel$Pt-Ads[0.48]), however, displayed considerable diﬀerences
with respect to cumulative platinum release (% M/Mtot)
compared to all the other groups (Fig. 6b and d).
When the Pt–BP/GAmolar ratio was increased up to 0.12, 0.24
and 0.48, gelatine nanoparticles functionalised with Pt–BP did
not show more Pt–BP retention as compared to the correspond-
ing gelatine nanoparticles containing adsorbed Pt–BP (Fig. 6a
and c). Interestingly, even at the highest Pt–BP/GA ratio of 0.48,
more than 80 wt% of the Pt–BP initially present on the gelatine
nanoparticles was retained to the nanoparticles aer 14 days of
soaking. Pt–BP generally showed strong retention (higher than 75
wt%) to both types of gelatine nanoparticles containing Pt–BP
(adsorbed or functionalised) aer 14 days (Fig. 6a and b).
Nevertheless, the extent at which Pt–BP can be loaded onto
(Fig. 3) and released from gelatine nanoparticles is limited when
Pt–BP is adsorbed. For functionalised gelatine nanoparticles, on
the other hand, it is possible to adjust the desired amount of
released Pt–BP by varying the Pt–BP/GA molar ratio.
Fig. 7a compares the retention of Pt–BP to dual-
functionalised gelatine nanoparticles versus gelatine nano-
particles functionalised with Pt–BP only. The results revealed
that dual-functionalisation did not have a considerable inu-
ence on the retention eﬃciency of Pt–BP to gelatine nano-
particles as compared to those functionalised with Pt–BP only.
Furthermore, Pt–BP generally showed strong retention (higher
than 80 wt%) to dual-functionalised gelatine nanoparticles.
Cumulative platinum release (% M/Mtot) from dual-
functionalised gelatine nanoparticles increased by increasing
Fig. 5 Eﬀect of Pt–BP/GA molar ratio on the eﬃciency of dual-
functionalisation of gelatine nanoparticles measured by ICP-OES (Y
axis represents wt% of Pt–BP and ALN present in gelatine nano-
particles) (p < 0.05).
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the Pt–BP/GA molar ratio, which was similar to gelatine nano-
particles functionalised with Pt–BP only (Fig. 7b–d show
statistical analysis of Fig. 7a and b, respectively, for day 14 only).
Similar to the results obtained for Pt–BP-adsorbed and Pt–
BP-functionalised gelatine nanoparticles (Fig. 6b), dual-
functionalised gelatine nanoparticles displayed increased
cumulative platinum release (Fig. S5b and d†) for all Pt–BP/GA
molar ratios, when compared to those with adsorbed Pt–BP and
ALN. For dual-functionalised gelatine nanoparticles, however, it
was possible to detect diﬀerences in Pt–BP retention, when
compared to those with adsorbed Pt–BP and ALN (Fig. S5a and
c†). Nevertheless, it should be emphasised that even gelatine
nanoparticles adsorbed with Pt–BP and ALN displayed high Pt–
BP retention properties aer 14 days (approximately higher
than 65% for the group with the highest Pt–BP/GAmolar ratio of
0.48 (Gel$Pt$ALN-Ads[0.48])).
Fig. 6 (a) Weight percentage of Pt–BP retained to Pt–BP-functionalised versus Pt–BP-adsorbed gelatine nanoparticles as a function of soaking
time and Pt–BP/GA molar ratio; (b) cumulative release of total amount of platinum relative to platinum initially detected on 10 mg of gelatine
nanoparticles (%M/Mtot) as a function of soaking time and Pt–BP/GA molar ratio; (c) and (d) statistical analysis of (a) and (b), respectively, for day
14 only (*: p < 0.05; NS: not statistically diﬀerent).
Fig. 7 (a) Weight percentage of Pt–BP retained to dual-functionalised versus Pt–BP-functionalised gelatine nanoparticles as a function of
soaking time and Pt–BP/GA molar ratio; (b) cumulative release of total amount of platinum relative to platinum initially detected on 10 mg of
gelatine nanoparticles (%M/Mtot) as a function of soaking time and Pt–BP/GAmolar ratio; (c) and (d) statistical analysis of (a) and (b), respectively,
for day 14 only (*: p < 0.05; NS: not statistically diﬀerent).
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The Pt–BP conjugation reaction resulted into signicantly
improved retention of Pt–BP to dual-functionalised gelatine
nanoparticles as compared to nanoparticles which were loaded
with Pt–BP and ALN by physical adsorption only. The increased
amount of Pt–BP linked to chemically functionalised gelatine
nanoparticles (Fig. 3) and the improved retention of Pt–BP on
dual-functionalised gelatine nanoparticles (Fig. S5†) was
attributed to the formation of covalent imine linkages between
aldehyde groups at the nanoparticle surface and the pending
amine group of the Pt–BP complex. Fig. 8 shows potential
schemes for the reactions between ALN (Fig. 8a) and the Pt–BP
complex (Fig. 8b) with aldehyde residues as present on gelatine
nanoparticles. The hydrolytic stability of this bond was more
than two weeks, which would be suﬃcient for the intended
applications. Moreover, in the tumour microenvironment,
where protease such as matrix metalloproteinases (collagenase
and gelatinase) are highly expressed, the proteolytic degrada-
tion of the gelatine nanoparticles could possibly occur at
a faster rate than in the blood with the simultaneous increased
release of the Pt–BP complex.69,70 Several studies from our group
conrmed that release of loaded compounds from gelatine
nanoparticles is controlled by proteolytic enzymes when suﬃ-
ciently strong bonds are formed between the loaded
compounds and gelatin carriers.71–73 The results presented in
the current study showed that Pt–BP complex displays
a considerable retention to gelatine nanoparticles; therefore, it
can be assumed that the release of linked Pt–BP from these
(dual-)functionalized nanoparticles will also be controlled to
a certain extent by proteolytic enzymes. This, however, should
be investigated in more details, e.g. by using radioactive 195mPt.
The fast release of 15–20 wt% of platinum from (dual-)
functionalised gelatine nanoparticles at 0.12, 0.24 and 0.48
Pt–BP/GA molar ratios (Fig. 6, 7 and S5†) was attributed to
physically entrapped Pt–BP rather than cleavage of imine
bonds. This phenomenon was in line with the broadly reported
burst release of various biomolecules adsorbed onto or encap-
sulated inside gelatine nanoparticles without formation of
Fig. 8 Potential schemes for the reaction between (a) ALN and (b) Pt–
BP complex with aldehyde residues on gelatine nanoparticles.
Fig. 9 Fluorescence images of hydroxyapatite-coated titanium discs immersed in suspensions of (a) Gel, (b) Gel$Pt[0.06], (c) Gel$Pt[0.48], (d)
Gel$ALN and (e) Gel$Pt//ALN[0.48] (scale bar ¼ 1 mm). (f) Quantiﬁcation of the ﬂuorescence intensity derived from the autoﬂuorescence of
surface-bound gelatine nanoparticles (p < 0.05).
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covalent bonds between the biomolecules and the polymeric
macromers.12,45,74–76
By comparing the ALN retention of dual-functionalised
gelatine nanoparticles with ALN-functionalised gelatine nano-
particles (Fig. S6†),12 we observed that dual-functionalisation
decreased the retention of ALN to gelatine nanoparticles from
approximately 70 wt% down to approximately 50 wt%.
Increasing the Pt–BP/GA molar ratio, however, did not aﬀect the
retention of ALN of the dual-functionalised gelatine nano-
particles. These ndings suggest that the aﬃnity of mineral-
binding ALN-functionalised gelatine nanoparticles to calcium
phosphate (CaP) could be maintained even aer dual-
functionalisation with high amounts of Pt–BP.
Aﬃnity of gelatine nanoparticles to calcium phosphate. To
investigate the eﬀect of Pt–BP-functionalisation as well as dual-
functionalisation on the aﬃnity of unfunctionalised and ALN-
functionalised gelatine nanoparticles to CaP surfaces,
hydroxyapatite-coated titanium discs (corresponding XRD and
ATR-FTIR spectra are reported in Fig. S7a and b,† respectively)
were immersed in gelatine nanoparticle suspensions. Pure
titanium discs, hydroxyapatite-coated titanium discs, ALN and
Pt–BP did not generate any autouorescence. Consequently, the
detected uorescence could be only attributed to the auto-
uorescence of gelatine nanoparticles. Digital image analysis of
uorescence micrographs of hydroxyapatite-coated titanium
discs revealed that Pt–BP-functionalisation (Fig. 9a–c) did not
increase the aﬃnity of gelatine nanoparticles to hydroxyapatite
surfaces (Fig. 9f). This nding is not surprising, since all the
oxygen atoms of the bisphosphonate are bound to platinum.
ALN- (Gel$ALN) or dual-functionalisation (Gel$Pt//ALN[0.48]) of
gelatine nanoparticles (Fig. 9d and e, respectively), however,
resulted into approximately sixfold higher uorescence inten-
sity on the hydroxyapatite surfaces compared to unfunctional-
ised or Pt–BP-functionalised gelatine nanoparticles. Gelatine
nanoparticles dual-functionalised with lower Pt–BP/GA molar
ratios (0.06, 0.12 and 0.24) also showed similar uorescence
intensities on the hydroxyapatite surfaces as shown in Fig. 9e
for Pt–BP/GA molar ratio of 0.48 (data not shown). These results
demonstrate that mineral-binding gelatine nanoparticles
functionalised with Pt–BP molecules did not lose their mineral-
binding capacity.
Conclusions
This study presents a conjugation strategy for the preparation of
gelatine nanoparticles functionalised with a chemotherapeutic
platinum–bisphosphonate (Pt–BP) complex or dual-
functionalised with Pt–BP and mineral-binding alendronate
(ALN). The degree of functionalisation could be tuned by
varying the molar ratio of Pt–BP and ALN relative to glutaral-
dehyde used as crosslinker. Sustained and tuneable release of
platinum was observed from both Pt–BP- and dual-
functionalised gelatine nanoparticles. Moreover, dual- and
ALN-functionalised gelatine nanoparticles displayed a high
aﬃnity to calcium phosphate as a result of functionalisation
with ALN. Summarising, it can be concluded that mineral-
binding gelatine nanoparticles can be functionalised with
chemotherapeutic drugs, whichmay benet the development of
bone-seeking and potentially chemotherapeutically active
carriers for treatment of bone tumours.
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